#ADA2022 – RCT: Once-weekly dulaglutide for the treatment of youths with type 2 diabetes.

Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Once Weekly Drug Helps Control Pediatric Type 2 Diabetes – American Diabetes Association

Commentary on Twitter

Trial compared once-weekly dulaglutide with placebo for glycemic control in youths with type 2 diabetes who may have been receiving metformin or basal insulin. Dulaglutide was superior at 26 weeks. #ADA2022 https://t.co/P6PubXvHOR pic.twitter.com/1JPIT5IyTe

— NEJM (@NEJM) June 4, 2022